REPRIEVE and CANTOS trials: lessons learned towards eliminating cardiovascular disease in human immunodeficiency virus by combined targeting of LDL and inflammation.

IF 10.2 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Research Pub Date : 2024-09-09 DOI:10.1093/cvr/cvae152

Annet Kirabo

引用次数: 0

查看原文本刊更多论文

REPRIEVE 和 CANTOS 试验：通过联合针对低密度脂蛋白和炎症消除人类免疫缺陷病毒心血管疾病的经验教训。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Research 医学-心血管系统

CiteScore

21.50

自引率

3.70%

发文量

547

审稿时长

1 months

期刊介绍： Cardiovascular Research Journal Overview: International journal of the European Society of Cardiology Focuses on basic and translational research in cardiology and cardiovascular biology Aims to enhance insight into cardiovascular disease mechanisms and innovation prospects Submission Criteria: Welcomes papers covering molecular, sub-cellular, cellular, organ, and organism levels Accepts clinical proof-of-concept and translational studies Manuscripts expected to provide significant contribution to cardiovascular biology and diseases